Pfizer Raises 2026 Revenue Outlook After Strong Q2
Pfizer reported second-quarter revenue of $15.03 billion, exceeding expectations, and raised the midpoint of its full-year revenue guidance. The company now projects full-year 2026 revenue between $60.5 billion and $62.5 billion, up from the previous range of $59.5 billion to $62.5 billion. The improved outlook is attributed to stronger-than-expected performance from recently launched and acquired products. The announcement was made on Tuesday, following the release of quarterly earnings. This positive financial update reflects Pfizer's ongoing efforts to bolster its portfolio through new product launches and strategic acquisitions, positioning the company for sustained growth in the coming years.
Key facts
- Pfizer reported Q2 revenue of $15.03 billion.
- Full-year 2026 revenue guidance raised to $60.5-$62.5 billion.
- Previous guidance was $59.5-$62.5 billion.
- Strong performance from recently launched and acquired products.
- Earnings exceeded expectations.
- Announcement made on Tuesday.
- Company raised midpoint of revenue guidance.
Entities
Institutions
- Pfizer
Sources
- Quartz —